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Effect of aluminum on bone matrix inductive properties. The effect of
aluminum on the bone inductive properties of implanted bone matrix
was studied in rats. After decalcification femur sections were placed in
either 0.1 or 0.01 M AICI3 or a solution of similar pH without Al for 24
hours. Following 28 days of implantation in subcutaneous pouches the
aluminum content was 3232 1020 and 51 6 mg/kg in the matrix
pretreated with 0.1 and 0.01 M AId3. At the same time period following
implantation the matrix calcium content was 794 539 and 3038 692
mmol/kg in the 0.1 and 0.01 M AId3 pretreated groups versus 4252
579 mmol/kg in the control group (P < 0.01). In the control group bone
histology showed extensive osteoblastic and osteoclastic remodeling,
tetracycline labeling and bone formation. In contrast all of these
histological features were virtually absent in aluminum treated matrix.
Aluminum-induced resistance of bone matrix to collagenase degrada-
tion and restoration of bone inductive properties with chelation sug-
gests that aluminum forms intermolecular cross links between collagen
fibrils. Aluminum-induced cross links of collagen fibrils and/or its
effects on bone inductive proteins present in bone matrix could explain
the mechanism by which aluminum induces osteomalacia.
The association between aluminum and osteomalacia in hu-
mans with renal disease has been well established [IL In
addition, aluminum causes osteomalacia in a number of dif-
ferent animal species including dogs, rats and pigs [2—4].
Aluminum has been shown to produce a number of effects
which could alter bone formation. It has been shown in organ
cultures that aluminum inhibits the synthesis of bone alkaline
phosphatase and acid phosphatase, implying that aluminum
may affect osteoblast and osteoclast function [5]. Furthermore,
aluminum has been shown to cause a reduction in the number of
osteoblasts and osteoclasts suggesting it could be directly toxic
to these cells (6]. Other studies have found that aluminum has a
direct effect on preventing the physical and chemical events
leading to calcium-phosphate crystal formation [7].
Two features make aluminum associated osteomalacia
unique. It is resistant to vitamin D treatment [8] and, unlike
most other osteomalacic states, it occurs in the setting of
hyperphosphatemia, mild hypercalcemia and an increased cal-
cium X phosphate product [9]. These findings imply that the
osteomalacia could result from an aluminum-induced alteration
in bone matrix which renders it uncalcifiable. Consistent with
this is histochemical staining which reveals that aluminum is
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present at the osteoid junction between calcified and non-
calcified bone in aluminum-associated osteomalacia [10].
Historically aluminum has been used as a tanning agent
because of its ability to cause intermolecular cross linkage of
collagen fibrils [11]. Thus it would be expected that aluminum
could also increase intermolecular cross linkage of bone colla-
gen, bonding the aluminum to matrix, which could alter its
ability to induce bone formation.
The present study was undertaken to determine how pretreat-
ment of decalcified bone matrix with aluminum would affect its
bone inductive properties and its ability to calcify.
Methods
Preparation of bone matrix
Bone matrix was prepared using a modification of the method
described by Urist et al [121. Femurs were immediately re-
moved from dead male Sprague-Dawley rats and sawed perpen-
dicular to the shaft to obtain sections approximately 2.4 mm
thick. The bone sections were cleaned of periosteal and en-
dosteal tissues, washed several times in sterile distilled water
and decalcified in 0.6 M HCI (I g tissue in 100 ml HCI) at 2°C for
48 hours. Under these conditions bone has been shown to be
almost completly decalcified and to have minimal denaturation
of bone matrix [12]. The bone was then removed from the acid
and washed with sterile distilled water. After washing, the bone
matrix was placed in 0.1 M or 0.01 M AId3 or 0.001 M HCI for
24 hours at 2°C. The pH of the respective solutions was 3.6,
3.71 and 3.55 at the initiation of treatment and 3.67, 4.1 and 3.61
after the 24 hour incubation. In preparation for implantation the
bone matrix was washed with sterile distilled water. Additional
bone sections were decalcified and placed in either 0.001 M HCI
or 0.1 M AICI3 as described above. These sections were then
placed in a solution containing either 20 molIml deferroxamine
(DFO) or ethylenediamine tetracetic acid (EDTA) for an addi-
tional 24 hours.
Implantation of bone matrix
Male weanling Spraque-Dawley rats approximately four
weeks old (weighing 80 to 100 g) were used for the recipients of
the bone matrix. Two aluminum-treated matrix specimens and
two control (HCI treated) specimens were implanted under
sterile conditions into individual subcutaneous pouches (four)
dissected into the ventral abdominal wall of each rat. The
implants were removed at four and eight weeks following
implantation. Matrix, untreated with aluminum, was implanted
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into four rats which received 1.5 mg/kg/day aluminum i.p. for 28
days following the implantation of matrix.
Collagenase incubation
Decalcified bone matrix was prepared as described above and
placed in 0.1, 0.01, 0.001 M Aid3 or 0.001 M HCI at 2°C for 24
hours. The matrix was then washed, dried at room temperature
and weighted. Each matrix specimen was placed in 4 ml of
water containing 25 mg of collagenase (Worthington Biochem-
ical Corporation, Freehodi, New Jersey, USA) for 15 hours at
37°C. The residual matrix was removed from the collagenase,
air dried at room temperature for 48 hours and reweighed.
In vitro nucleation of calcium-phosphate crystals
A modification of the method described by Strates and
Neuman [13] was used. The calcification solution consisted of
15 m barbital buffer, pH 7.4, 100 mM NaCI, 1.7 mM CaCl2 and
1.7 m potassium phosphate. Three to four mg samples of bone
matrix pretreated with either 0.1 or 0.01 M Aid3 or 0.001 M HCI
were placed in the solution for 24 hours at 35°C. The specimens
were then removed from the solution and analyzed for calcium
as described below.
Analytical procedures
For aluminum and calcium determinations the bone matrix
was dried to a constant weight at 105°C. The matrix was
extracted with a saturated solution of EDTA at 25°C for three
days. Calcium and aluminum determinations were performed
by previously described methods [14, 15].
For histological studies rats with matrix implants were given
tetracycline (16 mg/kg) five, three and one day(s) prior to
removal of the implants. Following removal, the bone matrix
was immediately placed into cold methanol. It was then embed-
ded in glycol methacrylate for processing. The non-decalcified
specimens were stained with either hematoxylin and eosin, acid
fuschin or Von Kossa stain for routine histological studies or
aurin tricarboxylic acid for aluminum.
All results are given as mean I SD. Statistical comparisons
were carried out with Student's f-test for two groups and
analysis of variance for multiple group comparisons.
Results
The tissue aluminum in unimplanted matrix pretreated with
0.1 si Aid3 was 4988 473, 3232 1020 after 28 days of
implantation and 2855 865 mg/kg after 56 days of implantation
(Fig. 1). The tissue aluminum in unimplanted matrix pretreated
with 0.01 M AICI3 was 395 4 prior to implantation and 51 6
mg/kg after 28 days of implantation. In the matrix treated only
with HCI aluminum was less than 2 mg/kg both before and after
implantation.
The tissue calcium content in unimplanted bone matrix
treated with AId3 or HCI was less than I mmol/kg dry weight.
Following 28 days of implantation the tissue calcium content
was 4252 579 in the control tissue, 3038 692 in the tissue
pretreated with 0.01 M AId3 and 794 539 mmol/kg in the
tissue pretreated with 0.1 M AId3 (P < 0.01 between all
groups). Following 56 days of implantation the calcium was
4642 242 in the control tissue and 593 380 in the tissue
pretreated wth 0.1 M AICI3 as compared to 6354 242 mmol/kg














Histological examination of the control tissue following 28
and 56 days of implantation revealed extensive tetracycline
labeling, bone formation and remodeling with numerous osteo-
blasts and osteoclasts (Figs. 2, 3). In contrast in the matrix
pretreated with 0.1 M AId3 following both 28 and 56 days of
implantation, there was almost total absence of bone formation
as shown by no tetracycline labeling and little evidence of
cellular activity (Fig. 4). Of further interest was the fact that the
implanted matrix pretreated with 0.1 M AICI3 was virtually
unchanged from its pre-implanted appearance. It had incited
little if any tissue reaction and had undergone virtually no
degradation. In contrast the untreated matrix had assumed the
appearance of the implanted femur section prior to decalcifica-
tion (Fig. 4). In the matrix pretreated with 0.01 M AICI3 and
removed 28 days following implantation, there were islands of
bone formation within the matrix but much less bone than in the
control tissue. The control group showed no staining with the
0 28 56
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Fig. 1. Aluminum concentration in matrix exposed to 0.1 M AId3
before implantation (N = 4), and 28 (N 8) and 56 (N = 6) days
following implantation.
FIg. 2. Tetracycline labels (2 light lines on surface, arrows) in un-
treated matrix after 28-days of implantation.
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Fig. 4. Matrix treated with 0.1 si Aid3 (left) and control (right) after 28
days of implantation. There is no cellular activity or bone formation in the
treated matrix.
Fig. 3. Osteoblastic and osteoclastic activity with bone formation and
osteoid deposition in untreated matrix implanted for 28 days. Abbrevi-
ations are: Ost, osteoid; Osb, osteoblast; Cb, calcified bone; Oci,
osteoclast; M, marrow.
aluminum stain, whereas, the aluminum group showed diffuse
staining of the entire matrix.
Following chelation with DFO and EDTA the bone matrix
aluminum was less than 3 mg/kg in both control and aluminum
pre-treated matrix before and after implantation. In the DFO
groups, calcium content of the implant was 2691 279 versus
2693 407 mmollkg in the aluminum pre-treated and control
tissues (P = NS). Similarly in the EDTA groups there was no
difference between calcium content of aluminum pre-treated
and control matrix (2612 693 vs. 2789 104 mmollkg, P =
NS).
Bone matrix aluminum prior to collagenase treatment was
4988 473, 395 4 and 115 13 mg/kg in the three groups
pretreated with aluminum (0.1, 0.01 and 0.001 M AId3). The
percent of bone matrix which had not undergone degradation
after collagenase treatment was 93 4, 70 18, 33 22% in
the three aluminum groups (Fig. 5) as compared to 15 8% in
the controls (P < 0.05 between all groups).
In contrast to the in vivo results, pretreatment of bone matrix









Fig. 5. Percent of matrix remaining after 15 hours of incubation with
collagenase in control matrix treated with HCI and matrix treated with
0.001 M, 0.01 M and 0.1 MAId3 (each group N = 4).
a metastable solution. The tissue calcium content was 109 18
and 34 5 mmol/kg in matrix pretreated with 0.1 and 0.01 M
AId3, respectively (P < 0.01) as compared to 14 2 mmol/kg
in the control matrix (P <0.01).
To determine the effect of extracellular aluminum on bone
induction, bone matrix was implanted into four rats which
received i.p. aluminum injections daily over a 28 day period
following implantation. Plasma aluminum levels were 67.5
8.22 pg/liter six hours after aluminum injections as compared to
5 1 tgIliter in controls. At the end of the study matrix calcium
was 3700 455 mmol/kg in the aluminum treated group as
compared to 3790 226 mmollkg in the controls (P = NS).
Discussion
These studies show that aluminum treatment of decalcified
bone matrix markedly inhibits its bone inductive properties. In
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matrix resistance to degradation by collagenase and enhance its
in vitro calcification from a metastable solution.
An increased resistance of collagen to collagenase degrada-
tion has been attributed to increased maturity and cross linking
[16]. In this case it seems highly likely that this resulted from
increased cross linkage caused by the aluminum. Additional
support for aluminum cross linkage of collagen is the finding
that the aluminum pre-treated bone matrix was virtually total
intact after 56 days of implantation. It has previously been
shown that cross linked collagen is not only resistant to
collagenase degradation in vitro but it is also resistant in vivo to
degradation [17].
Mineral tannage has been extensively used in the tanning
industry. While chrome has been the most widely used element,
aluminum and zirconium have also been employed [17]. In this
form of tannage cross links are through chrome or aluminum
coordination complexes containing hydroxol, oxo, phosphate
or sulfate bridges into which carboxyl groups on collagen enter
forming the cross links. This provides the most hydrothermally
stable and commercially important tannages [18]. In further
support for aluminum-inhibiting bone matrix inductive proper-
ties by cross linkage of collagen fibrils is the fact that this
inhibitory property is completely reversed by the removal of
aluminum from the matrix by chelation. This is a well known
method of detanning metal tannages [11].
Additional evidence for the chemical bonding of aluminum in
bone matrix is the rather constant uptake of aluminum by
matrix from solutions containing various concentrations of
aluminum. Further support comes from the finding that at least
one compartment of aluminum in matrix is very stable as
supported by the minimal change in matrix aluminum concen-
tration which occurred between 28 and 56 days of implantation.
The fact that aluminum was found to enhance the calcifi-
ability of matrix from an in vitro metastable solution is addi-
tional evidence that aluminum alters the structure of bone
collagen probably through increasing cross linkage. Increased
cross linking may predispose collagen to develop dystrophic or
metastatic calcification. This is suggested by the fact that cross
linking collagen with glutaraldehyde predisposes pericardial
bioprosthetic heart valves to calcify [19]. Bovine pericardium
does not have bone inductive properties; therefore, its calcifi-
cation would appear to be of the dystrophic or metastic type.
However, aldehyde cross links are different from those formed
by minerals. Aldehyde cross linking results from the formation
of stable covalent cross links associated with a relatively limited
number of amine groups available on collagen [17].
Irrespective of aluminum's effect on promoting dystrophic
calcification of collagen, which might account for most of the
calcium present in matrix treated with 0.1 M AId3, it would
appear that its major effect on bone matrix was the eradication
of its bone inductive capabilities. Reddi, Wientroub and Muth-
ukumaran have extensively studied the bone inductive proper-
ties of decalcified bone matrix [20]. Normally within the first
week following implantation there is vascular invasion and the
appearance of chrondroblasts and chrondrocytes with cartilage
formation in the implant and subsequent calcification of the
cartilage. In a matter of days this is followed by the presences
of osteoblasts and osteoclasts with extensive bone formation,
remodeling and dissolution of the implanted matrix. In the
control implants the expected extensive bone formation and
remodeling was observed. However, in the aluminum treated
matrix there was virtually no cellular activity and very little
bone formation in the implant. This would suggest that alumi-
num treatment of matrix prevented calcification by suppressing
matrix bone inductive ability and cellular involvement in this
process. This is also supported by the vitro data showing that
aluminum enhances the ability of collagen to calcify which
tends to exclude a basic alteration in collagen which prevents its
calcification. This loss of inductive ability of bone matrix could
also explain why there is a decrease number and function of
osteoblasts and osteoclasts in organ cultures which have been
treated with aluminum.
The presence of aluminum in the matrix is required for this
inhibitory effect since chelation of aluminum restores the bone
inductive properties. This inhibitory effect could result from
aluminum cross links of the collagen fibrils. However, it has
been suggested that collagen is not necessary for the bone
inductive properties of matrix [21]. Somewhat against this is the
fact that the osteo-inductive components of bone have been
shown to be ineffective in causing bone formation in tendons,
also type I collagen [22]. Because of this, it has been suggested
that bone collagen might be a more suitable substratum for
anchorage-dependent proliferation and differentiation of cells
capable of bone formation [221. This would be consistent with
the finding in this study showing that bone formation in the
implanted matrix resembled the implant prior to being decalci-
fled. It is possible that aluminum-induced cross links of collagen
could either immobilize the bone inductive proteins or simply
the presence of aluminum in matrix could somehow have a
direct effect on inhibiting bone induction. In further support
that aluminum bound in matrix is responsible for inhibiting bone
induction is the fact that i.p. injected aluminum, which in-
creased plasma aluminum and presumably extracellular fluid
aluminum, had no effect on the bone inductive property of
matrix.
Irrespective of the mechanism by which aluminum inhibits
bone induction it requires only a small amount, less than 50 mg
aluminumlkg matrix, to suppress bone formation. Whole bone
aluminum obtained from uremic patients with osteomalacia
typically have much higher bone aluminum levels than this [23].
In addition, the bone aluminum in osteomalacic bone tends to
be concentrated in the osteoid, making it even more likely that
it could alter the osteoid structure and its ability to promote
bone formation.
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